VIA
ZYNE

Vident Investment Advisory’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Vident Investment Advisory’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-105,398
Closed -$77K – 1368
2022
Q3 		$77K Buy
105,398
+13,978
+15% +$15.9K ﹤0.01% 1078
2022
Q2 		$104K Buy
91,420
+7,443
+9% +$9.48K ﹤0.01% 1190
2022
Q1 		$172K Buy
83,977
+33,418
+66% +$79.5K ﹤0.01% 1205
2021
Q4 		$146K Buy
50,559
+1,958
+4% +$7.24K ﹤0.01% 1168
2021
Q3 		$206K Buy
+48,601
New +$217K 0.01% 1083

Other funds holding ZYNE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

Vident Investment Advisory's ZYNE Position: Q4 2022 in Review

Vident Investment Advisory sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2022, closing a stake of 105,398 shares — an estimated $77K sold.

Vident Investment Advisory first reported a position in ZYNE in Q3 2021 and held it in 5 quarters. The position peaked at $206K in Q3 2021. 50 funds tracked by Wall St. Rank hold ZYNE as of Q4 2022.

  • Vident Investment Advisory reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 105,398 Zynerba Pharmaceuticals, Inc shares in Q4 2022, an estimated $77K.
  • Vident Investment Advisory first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2021 and held it in 5 quarters.
  • Vident Investment Advisory's Zynerba Pharmaceuticals, Inc position peaked at $206K in Q3 2021.
  • 50 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.